Human Diploid Rabies Vaccine
The human diploid rabies vaccine is an inactivated virus vaccine used for the prevention of rabies. This vaccine is prepared using a virus grown in human diploid cell culture, which is then inactivated and purified for use. It is a safe and effective vaccine and is widely used in both pre-exposure and post-exposure prophylaxis of rabies.Pre-exposure prophylaxis: Individuals at high risk of exposure to rabies, such as veterinarians, laboratory workers, and travelers to high-risk areas. Post-exposure prophylaxis: Individuals who have been bitten, scratched, or otherwise exposed to a potentially rabid animal.
Pre-exposure prophylaxis: Typically, 3 doses are administered on days 0, 7, and 21 or 28. Post-exposure prophylaxis: The standard regimen includes 4 doses on days 0, 3, 7, and 14 (or 28 if immunocompromised). Additionally, rabies immunoglobulin (RIG) may be given on day 0 for those who have not been previously vaccinated.
Individuals with a history of a severe allergic reaction to any component of the vaccine should not receive it. The vaccine is contraindicated during acute illnesses or in cases of severe allergic reactions..
Immediate medical attention is necessary if signs of an allergic reaction (e.g., hives, difficulty breathing, or swelling) occur. Patients with compromised immune systems should discuss their options with a healthcare provider. Considerations should be given to possible interactions with other vaccines or medications.
Common: Pain, redness, swelling at the injection site, headache, fatigue, muscle pain, nausea, or dizziness. Less common: Allergic reactions such as rash, itching, and swelling. Rare: Severe allergic reactions (anaphylaxis).
Generally, the human diploid rabies vaccine can be administered with other vaccines such as tetanus or diphtheria without any known interactions. If receiving immunosuppressive treatments, patients may need to adjust their vaccination schedule or doses. Consult with a healthcare provider.
